Docket Number:14A-1020222
Inventor:Lie-Feng Shyur, Jia-Hua Feng, and Maria Karmella Apaya
IP Status:TW I558403、JP 6033255、CN ZL201410239259.1
Abstract:
This invention discloses that the plant extracts from the medicinal plant Crassocephalum rabens S. Moore (Asteraceae), also known as C. crepidioides S. Moore, can function as hepatoprotective or therapeutic agent against fulminant hepatitis and sepsis, or can be used for depigmentation purpose. Treatment with the plant extracts after induction of fulminant hepatitis by LPS/D-GalN in mice can significantly inhibit the increased levels of serum AST and ALT as those observed for the clinical drug silymarin (SM) for liver protection. LPS/D-GalN–challenge caused infiltration of inflammatory cells into liver lobules and tissue destruction and erythrocyte influx in liver tissues as compared to the vehicle control, and which was attenuated by both plant extracts and SM treatment. Furthermore, the plant extracts treatment also significantly decreased the number of apoptotic cells (TUNEL positive-stained cells) in the liver tissues of LPS/D-GalN–challenged mice. Further, the study results of LPS-induced sepsis in mice showed that LPS-induced acute liver, lung and kidney damages or inflammation in mice can be significantly and dose-dependently reduced by treatment with the plant extracts. Similar effects were observed in the positive control drug simvastatin. The expression of proinflammatory cytokines, i.e., TNF- and IL-6, and the enzymatic activity of AST and ALT induced by LPS in mice sera were significantly inhibited by dLGG, dLGG containing extracts and simvastatin. In the mean time, the EA fraction and dLGG derived from ethanolic extract of C. rabens also showed depigmentation effect in B16 melanoma cells through inhibiting MITF and tyrosinase expression in the cells. Together, this invention discovers that CR extracts and dLGG are potential preventive and therapeutic interventions for fulminant hepatitis, sepsis and sepsis-induced acute kidney injury. Further, CR extracts and dLGG are potential cosmetics used in skin-whitening
Fields of Application:
- Treatment of fulminant hepatitis, sepsis, and sepsis-induced acute kidney injury.
- Dietary supplement
- Cosmetics
Advantages when compared to the existing technologies:
Together, this invention discovers that plant extracts are potential preventive and therapeutic interventions for fulminant hepatitis, sepsis and sepsis-induced acute kidney injury. Further, the plant extracts are potential cosmetics used in skin-whitening
Contact Person:
對本技術有興趣,請於本處網頁廠商選項下(廠商需求與諮詢)網頁填寫資料,承辦人將跟您聯絡。
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Apply for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office, and the undertaker will contact you
